Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
06:00am, Thursday, 11'th Apr 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered
3 Buy-Rated Stocks Flexing Relative Strength
04:31pm, Wednesday, 10'th Apr 2024
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three c
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-
Exact Sciences Schedules First Quarter 2024 Earnings Call
06:00am, Monday, 08'th Apr 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 20
The 3 Best Cathie Wood Stocks to Buy in April 2024
04:16pm, Friday, 05'th Apr 2024
Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.
1 Beaten-Down Cathie Wood Stock to Buy and Hold
10:15am, Thursday, 04'th Apr 2024
Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
06:05am, Thursday, 04'th Apr 2024
ROCHESTER, Minn. & MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
11:01am, Wednesday, 03'rd Apr 2024
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
01:03pm, Tuesday, 02'nd Apr 2024
Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
06:00am, Thursday, 28'th Mar 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reporte
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Tuesday, 26'th Mar 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
10:56am, Monday, 25'th Mar 2024
The mean of analysts' price targets for Exact Sciences (EXAS) points to a 53.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 22'nd Mar 2024
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
09:20am, Monday, 18'th Mar 2024
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect?
10:55am, Friday, 08'th Mar 2024
The consensus price target hints at a 55.4% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
